Study: Immune therapy scores big win against lung cancer
(WorldNews Health)

CHICAGO - For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer. It´s the biggest win so far for immunotherapy, which has had much of its success until now in less common cancers. In the study, Merck´s Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone after nearly one year. The results are expected to quickly set a new standard of care for about 70,000 patients each year in the United States whose lung cancer has already spread by the time it´s found. Another study found that an immunotherapy combo - the...